West Pharmaceutical Services (NYSE:WST) Releases Q3 2026 Earnings Guidance

by · The Markets Daily

West Pharmaceutical Services (NYSE:WST – Get Free Report) updated its third quarter 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 2.140-2.240 for the period, compared to the consensus earnings per share estimate of 2.130. The company issued revenue guidance of $820.0 million-$835.0 million, compared to the consensus revenue estimate of $815.1 million. West Pharmaceutical Services also updated its FY 2026 guidance to 8.850-9.050 EPS.

West Pharmaceutical Services Stock Down 0.5%

Shares of NYSE:WST opened at $356.45 on Thursday. The company has a 50 day moving average of $335.41 and a 200-day moving average of $286.58. West Pharmaceutical Services has a one year low of $223.83 and a one year high of $392.88. The stock has a market cap of $25.18 billion, a price-to-earnings ratio of 48.68, a P/E/G ratio of 2.91 and a beta of 1.16. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.71 and a quick ratio of 2.04.

West Pharmaceutical Services (NYSE:WST – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. The firm had revenue of $872.30 million during the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, sell-side analysts forecast that West Pharmaceutical Services will post 8.6 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th will be issued a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio is presently 11.76%.

Wall Street Analyst Weigh In

WST has been the topic of a number of recent analyst reports. BNP Paribas Exane began coverage on shares of West Pharmaceutical Services in a report on Monday, July 13th. They set an “outperform” rating and a $447.00 target price on the stock. Evercore reissued an “outperform” rating and issued a $410.00 price objective on shares of West Pharmaceutical Services in a research report on Monday, July 6th. KeyCorp upped their target price on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd. Wolfe Research assumed coverage on shares of West Pharmaceutical Services in a research note on Monday, June 1st. They issued an “outperform” rating and a $375.00 target price for the company. Finally, Weiss Ratings raised West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, April 27th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $363.17.

Get Our Latest Analysis on West Pharmaceutical Services

Insider Buying and Selling at West Pharmaceutical Services

In related news, VP Annette F. Favorite sold 2,817 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the transaction, the vice president directly owned 16,828 shares in the company, valued at approximately $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer directly owned 1,523 shares in the company, valued at approximately $457,920.41. This represents a 37.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.60% of the stock is owned by company insiders.

West Pharmaceutical Services News Roundup

Here are the key news stories impacting West Pharmaceutical Services this week:

  • Positive Sentiment: West Pharmaceutical posted Q2 2026 EPS of $2.37, ahead of the $2.08 consensus, while revenue of $872.3 million also topped estimates. The beat suggests strong operating momentum and is a key reason investors are bidding up the stock. West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars
  • Positive Sentiment: The company raised its 2026 outlook, guiding EPS to $8.85-$9.05 versus the prior/consensus view around $8.61, and revenue to about $3.3 billion-$3.4 billion. Higher guidance often supports the stock because it signals confidence in continued demand and earnings growth. West Pharmaceutical raises annual profit forecast on strong demand for injectable drug components
  • Positive Sentiment: Management also lifted Q3 2026 guidance, forecasting EPS of $2.14-$2.24 and revenue of $820 million-$835 million, both modestly above expectations. This reinforces the view that the earnings beat was not a one-quarter event.
  • Positive Sentiment: Reuters noted demand remains strong for injectable-drug components tied to diabetes and obesity treatments, a favorable end-market trend that could continue to support West’s growth.

Institutional Investors Weigh In On West Pharmaceutical Services

Several institutional investors have recently made changes to their positions in the stock. Zions Bancorporation National Association UT raised its stake in West Pharmaceutical Services by 25.3% in the fourth quarter. Zions Bancorporation National Association UT now owns 312 shares of the medical instruments supplier’s stock valued at $86,000 after purchasing an additional 63 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in West Pharmaceutical Services during the fourth quarter worth about $207,000. Knollwood Investment Advisory LLC bought a new position in West Pharmaceutical Services in the 3rd quarter valued at about $220,000. Ausdal Financial Partners Inc. bought a new position in West Pharmaceutical Services in the 3rd quarter valued at about $220,000. Finally, Brooklyn Investment Group raised its position in shares of West Pharmaceutical Services by 81.3% in the 3rd quarter. Brooklyn Investment Group now owns 816 shares of the medical instruments supplier’s stock valued at $214,000 after buying an additional 366 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors.

About West Pharmaceutical Services

(Get Free Report)

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

Featured Articles